EPLR 1/2017 (Vol. 1)

Editorial

Sabrina Röttger-Wirtz

Seite 1 - 2

Pay-for-Delay Agreements in the EU Pharmaceutical Industry

Patent Law and Competition Law in Light of Lundbeck

Stefano Barazza

Seite 3 - 21

Austria ∙ Further Cuts in the Reimbursement of Medicinal Products

Maximilian Raschhofer

Seite 22 - 25

Belgium ∙ 'Sunshine' in Belgium: New Statutory Transparency Requirements for Life Sciences Companies

Eveline Van Keymeulen, Tine Carmeliet

Seite 26 - 30

Denmark ∙ Latest Developments in Danish Healthcare Professional Transparency Regulation

Emil Bjerrum, Martin Dræbye Gantzhorn

Seite 31 - 36

Germany ∙ The Albiglutide Controversy: A Paradigm Shift in Pricing Negotiations?

Christian Stallberg

Seite 37 - 41

The Court as Pontius Pilate: Reflecting on Missed Opportunities in the PIP Decision open-access

Marco Rizzi

Seite 42 - 48

Jurisdiction

Seite 49 - 51

New EU Pharmaceutical Law and Policy

Seite 52 - 53